Diffusion and DCE-MRI were performed at baseline and 2-3 days following Crolibulin (EPC2407) treatment in a phase 1 clinical study of this vascular disrupting agent (VDA). Several functional parameter maps were computed and co-registered across scan dates in 11 subjects with advanced solid tumors. We measured changes in these MRI parameters that indicate cell swelling and vascular reduction following treatment. We identified multivariate combinations of changes in these MRI parameters that are correlated with the dose, AUC and Cmax of Crolibulin, respectively, information that can guide Crolibulin dosing in clinical trials of this VDA in combination with cytotoxic drugs.
How to access this content:
For one year after publication, abstracts and videos are only open to registrants of this annual meeting. Registrants should use their existing login information. Non-registrant access can be purchased via the ISMRM E-Library.
After one year, current ISMRM & ISMRT members get free access to both the abstracts and videos. Non-members and non-registrants must purchase access via the ISMRM E-Library.
After two years, the meeting proceedings (abstracts) are opened to the public and require no login information. Videos remain behind password for access by members, registrants and E-Library customers.
Keywords